38 NOTES TO THE FINANCIAL STATEMENTS continued 2.
Income 2012 2011 000 000 Income from listed investments UK dividends 41,547 39,841 Scrip dividends 743 689 Overseas dividends 10,527 9,314 Income from money market funds 9 9 52,826 49,853 Other income Interest on VAT recovered on management fees note 3 18 2,459 Underwriting commission 13 148 Total income 52,857 52,460 A GlaxoSmithKline special dividend of 398,000 2011: nil has been recognised in capital.
Investment Management Fees 2012 2011 REVENUE CAPITAL TOTAL REVENUE CAPITAL TOTAL 000 000 000 000 000 000 Investment management fee 1,662 3,877 5,539 1,464 3,417 4,881 Performance fee 3,584 3,584 1,662 7,461 9,123 1,464 3,417 4,881 Details of the investment management agreement are disclosed on page 24 in the Report of the Directors.
At 31 March 2012 investment management fees of 485,000 2011: 435,000 were accrued.
During the year, no amounts in respect of VAT recovered on management fees has been recognised 2011: 3,176,000.
Interest of 18,000 2011: 2,459,000 was received during the year in respect of VAT recovered in previous periods and is credited wholly to revenue.
Other Expenses 2012 2011 REVENUE CAPITAL TOTAL REVENUE CAPITAL TOTAL 000 000 000 000 000 000 Other expenses 776 1 777 775 1 776 Other expenses include the following: Directors fees 190 190 171 171 Fees payable to the Companys auditor in relation to: the audit of the financial statements 23 23 22 22 for other services 7 7 7 7 The maximum Directors fees authorised by the Articles of Association are 250,000 per annum.
The Directors Remuneration Report provides further information on Directors fees for the year.
Fees payable to the Companys auditor for other services relate to fees and expenses payable to the auditor for their review in connection with the half-yearly financial statements and the annual certificate to the trustee of the debenture stocks, which are recognised in revenue.
Fees payable to the Companys auditor are shown excluding VAT, which is included in other expenses.
